Posts

Microbiome Insights included in list of BC’s top emerging life sciences companies

/in /by

 

MARCH 14, 2018 — Microbiome Insights is honoured to be featured in the 2018 Emerging Rocket List by the management consulting firm Rocket Builders. The Emerging Rocket List is part of “Ready to Rocket”, a business recognition program that showcases British Columbia’s technology companies with the greatest potential for revenue growth as well as investment and market breakthrough.

The Ready to Rocket program encompasses 4 technology sectors: Information and Communications Technology, Cleantech, Life Science, and Digital Health. Microbiome Insights was one of the 10 companies included in the Emerging Rocket Life Science List, winning this recognition for the second year in a row.

Lists in the Ready to Rocket program are predictive of success; since 2003, the program has accurately identified future growth leaders in each category through rigorous sector and company analyses spanning several months.

To qualify as a candidate in the Life Science category, companies must have established industry relationships and must also be undergoing customer validation and regulatory approval. The selection committee assesses candidates based on early indicators of long-term potential and increasing shareholder value, such as passing key regulatory hurdles and achieving related validation steps.

“We identify companies that have both innovative technology and a fit within the industry value chain. Our analysis of the market and the company progress led to our selection of Microbiome Insights as a Ready to Rocket Life Science company,” said Thealzel Lee, Senior Partner, Rocket Builders.

Life sciences industry leaders form Microbiome Insights’ inaugural board of directors

/in /by

MAY 30, 2015 — Microbiome Insights, Inc. is pleased to announce the members of its inaugural Board of Directors (BOD). The members bring with them a wealth of knowledge from the global life sciences industry. Each one has achieved success in academic and/or industry roles and has contributed to groundbreaking advancements in their respective disciplines.

The members are:

Pieter Cullis, PhD, Director at the Life Sciences Institute, University of British Columbia.

Dr. Pieter Cullis brings decades of experience in research and business. He is, along with his colleagues in academia, responsible for many fundamental advances in the field of lipid nanoparticle systems for intravenous delivery of small molecule and macromolecular drugs. This work has led to three products which have been approved by regulatory agencies in the US and Europe, and a further five that have finished Phase 1 trials. Outside of his academic achievements, Dr. Cullis co-founded several biotech companies and has received many distinguished awards, including election to the Royal Society of Canada in 2004.

Brad Popovich, PhD, former Chief Scientific Officer at Genome BC

Dr. Brad Popovich has long been involved with Genome BC, serving on its Board of Directors from 2006-2011 and acting as the Chair for the Scientific Committee from 2008-2010. Alongside his current roles with Genome BC he serves as Chairman for the Genetic Information Management Systems and Director of the Centre for Drug Research and Development Ventures and Centre for Drug Development. His genetics expertise is in genetic counselling; he graduated with Masters degrees in genetic counselling and biochemical genetics, and was awarded a PhD in molecular genetics from McGill University. He also received postdoctoral training and a clinical fellowship in the lab of Nobel Laureate Oliver Smithies. Throughout his career, Dr. Popvich has held many titles as Director, Vice-President, and CEO of numerous companies and academic institutions—including founder and director of the Molecular Diagnostics Laboratory at Oregon Health Sciences University and founding member of the Oregon DNA Forensic Experts Panel.

Mike Fannon, Founder and CEO of BioIT Solutions.

Mike Fannon currently advises new biotechnology firms in the areas of information technology and customer relationship management, business strategy, and laboratory automation. He is CEO of BioIT solutions, a leading company specializing in advanced computational, workflow, and data-management systems for clinical diagnostics, drug development, and biotechnology research. He was the chief architect of BioIT’s innovative 1Platform4 software and was the former Vice President and Chief Information Officer at Human Genome Sciences, where he and his team developed computerized solutions to manage Human Genome Sciences’ R&D functions, high-volume labs, product development, and clinical trials. Mr. Fannon holds an MBA in Operations Analysis from American University and a Bachelors degree in Physics from Rollins College.